Peptilogics, Inc.
Peptilogics aims to revolutionize the discovery process for novel peptide therapeutics for serious and life-threatening diseases by combining peptide biology with machine learning, enabling drug design at massive scale through precision engineering and design. The company explores untapped chemical space to engineer peptides for challenging diseases, utilizing an AI platform called Nautilus™ for predictive peptide design, and focuses on advancing therapeutics with significant unmet medical needs. Their lead program, PLG0206, is an investigational peptide targeting periprosthetic joint infection, with promising preclinical and clinical data supporting its potential as a first-in-class treatment.
Industries
Nr. of Employees
small (1-50)
Peptilogics, Inc.
Products
PLG0206 (investigational peptide therapeutic)
An investigational broad-spectrum antibacterial peptide candidate characterized for rapid bactericidal and anti-biofilm activity; evaluated in nonclinical studies and early-phase clinical trials for prosthetic joint infections.
PLG0301 (investigational peptide program)
An investigational peptide program in preclinical development focused on infection and inflammation associated with cystic fibrosis.
Discovery-stage peptide programs (machine-learning designed)
Multiple discovery-stage programs applying AI-driven peptide design to therapeutic areas such as oncology and rare genetic disease; programs are in discovery or preclinical stages.
PLG0206 (investigational peptide therapeutic)
An investigational broad-spectrum antibacterial peptide candidate characterized for rapid bactericidal and anti-biofilm activity; evaluated in nonclinical studies and early-phase clinical trials for prosthetic joint infections.
PLG0301 (investigational peptide program)
An investigational peptide program in preclinical development focused on infection and inflammation associated with cystic fibrosis.
Discovery-stage peptide programs (machine-learning designed)
Multiple discovery-stage programs applying AI-driven peptide design to therapeutic areas such as oncology and rare genetic disease; programs are in discovery or preclinical stages.
Services
Strategic research collaborations
Collaborative partnerships with technology and biotechnology organizations to apply AI-driven peptide discovery and integrate compute or laboratory capabilities.
Strategic research collaborations
Collaborative partnerships with technology and biotechnology organizations to apply AI-driven peptide discovery and integrate compute or laboratory capabilities.
Expertise Areas
- AI-driven peptide discovery
- Peptide design and multiparameter optimization
- Automated peptide synthesis and scale-up
- Preclinical antimicrobial and anti-biofilm evaluation
Key Technologies
- Generative AI for peptide sequence design
- Predictive machine learning for multiparameter optimization
- On-prem high-performance computing (HPC) for deep learning
- Automated/design-scale peptide synthesizers